Company Performance Metrics
- Andrew Herr: Scientific FounderPast Role: Cincinnati Children’s, Associate Professor
- Kenneth Rice: President and Executive Officer
Chelexa BioSciences, Inc. is focused on infection prevention therapies for the skin. Our revenues and returns for our investors will come from development and commercialization of our proprietary, patent pending BioLexa™ biofilm prevention platform for human use in surgical site infections as well as acute and chronic wounds. In addition, we will
partner the BioLexa platform for use in companion animals in exchange for license fees, pre-commercial milestones, royalties and commitment by the licensee to fund all development and commercialization of the products in companion animals.
Chelexa’s product candidate, BioLexa, has the potential to prevent the formation of bacterial biofilms in surgical site incisions as well as acute and chronic wounds. Hospital acquired infections and infected wounds cost the US healthcare system over $30 billion annually. Our product can dramatically lower this cost burden.
